<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2016-2-71-74</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-511</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ОЦЕНКА ФАКТОРОВ РИСКА РАЗВИТИЯ СЕРДЕЧНО-СОСУДИСТОЙ ПАТОЛОГИИ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ</article-title><trans-title-group xml:lang="en"><trans-title>EVALUATION OF CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стародубцева</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Starodubtseva</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>докторант кафедры пропедевтики внутренних болезней,</p><p>Воронеж</p></bio><bio xml:lang="en"><p>Voronezh</p></bio><email xlink:type="simple">starodubtsevairina1@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васильева</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vasilieva</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., зав. кафедрой терапии ИДПО,</p><p>Воронеж</p></bio><bio xml:lang="en"><p>Voronezh</p></bio><email xlink:type="simple">ludmilvasil@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Воронежский государственный медицинский университет им. Н. Н. Бурденко</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.N. Burdenko Voronezh State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>28</day><month>02</month><year>2016</year></pub-date><volume>0</volume><issue>2</issue><issue-title>РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ</issue-title><fpage>71</fpage><lpage>74</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Стародубцева И.А., Васильева Л.В., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Стародубцева И.А., Васильева Л.В.</copyright-holder><copyright-holder xml:lang="en">Starodubtseva I.A., Vasilieva L.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/511">https://russjcardiol.elpub.ru/jour/article/view/511</self-uri><abstract><sec><title>Цель</title><p>Цель. Установить взаимосвязь между уровнем провоспалительных цитокинов сыворотки крови и маркерами сердечно-сосудистой патологии у больных ревматоидным артритом (РА), поскольку коморбидные заболевания широко распространены у таких больных.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Были обследованы 620 больных РА (диагноз в соответ- ствии с критериями ACR/EULAR 2010), находившихся на стационарном лечении в отделении ревматологии в возрасте 43,4±10; 95,4% больных АЦПП положительны, активность по DAS 28 II, III; из них 85,4% женщин с продолжи- тельностью заболевания 3-15 лет. Уровень цитокинов (ИЛ-1 и ФНО-α) оценивали с использованием готовых коммерческих наборов ЕLISA и набора ФНО-α (“Пикон”, Россия). Кроме того, изучали содержание ЛПОНП, ТГ и высокочувствительного С-реактивного белка в сыворотке крови.</p></sec><sec><title>Результаты</title><p>Результаты. Анализ результатов исследования показал статистически достоверное повышение уровня ИЛ-1 и ФНО-α в сыворотке крови больных РА (p&lt;0,001). В результате корреляционного анализа установлена средняя и высокая статистически достоверная зависимость между показателями систолического артериального давления и уровнем цитокинов 0,742 (p&lt;0,02) и 0,521 (p&lt;0,05), ЛПОНП 0,621 (p&lt;0,01) и 0,578 (p&lt;0,05), ТГ 0,512 (p&lt;0,01) и 0,364 (p&lt;0,05), hs СРБ 0,821 (p&lt;0,05) и 0,632 (p&lt;0,05) по отношению к значениям ИЛ-1 и ФНО-α, соответственно.</p></sec><sec><title>Заключение</title><p>Заключение. Уровень провоспалительных цитокинов (ИЛ-1, ФНО-α) может быть непрямым фактором риска развития и прогрессирования артериальной гипертензии и атеросклероза у больных РА, что необходимо учитывать при обследовании и лечении таких пациентов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To find out the relation between the pro-inflammatory cytokines level in serum, and cardiovascular markers in rheumatoid arthritis (RA) patients, as the comorbidities are prevalent in this group of patients.</p></sec><sec><title>Material and methods</title><p>Material and methods. Totally, 620 RA patients studied with RA (diagnosis according to ACR/EULAR 2010 criteria), hospitalized to rheumatologic department at the age 43,4±10 y.; 95,4% of patients were positive for CCPA, activity by DAS 28 was II, III; of those 85,4% women with disease duration 3-15 y. Level of cytokines (IL-1 и TNF-α) was measured by ЕLISA assay and TNF-α assay (“Picon”, Russia). Also, VLDL, TG and hsCRP were measured in the serum.</p></sec><sec><title>Results</title><p>Results. Data analysis showed statistically significant increase of IL-1 and TNF-α in RA patients serum (p&lt;0,001). As a result of correlation analysis the moderate and strong significant relation was found between the values of systolic blood pressure and cytokines level — 0,742 (p&lt;0,02) and 0,521 (p&lt;0,05), VLDL 0,621 (p&lt;0,01) and 0,578 (p&lt;0,05), TG 0,512 (p&lt;0,01) and 0,364 (p&lt;0,05), hsCRP 0,821 (p&lt;0,05) and 0,632 (p&lt;0,05) respectively for IL-1 and TNF-α.</p></sec><sec><title>Conclusion</title><p>Conclusion. The level of pro-inflammatory cytokines (IL-1, TNF-α) might be a nondirect risk factor of development and progression of arterial hypertension and atherosclerosis in RA patients, that is necessary to take into account in such patients management.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>цитокины</kwd><kwd>воспаление</kwd><kwd>сердечно-сосудистая система</kwd><kwd>С-реактивный белок</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rheumatoid arthritis</kwd><kwd>cytokines</kwd><kwd>inflammation</kwd><kwd>cardiovascular system</kwd><kwd>C-reactive protein</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Michaud K. Comorbidities in rheumatoid arthritis. Best Practice &amp; Research Clinical Rheumatology 2007; 21 (5): 885-906.</mixed-citation><mixed-citation xml:lang="en">Michaud K. Comorbidities in rheumatoid arthritis. Best Practice &amp; Research Clinical Rheumatology 2007; 21 (5): 885-906.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mazurov VI, Stolov CB, Zarajskij MI. The immunological mechanisms in the pathogenesis of coronary atherosclerosis Terapevticheskij arhiv. 2005; 77 (9): 24-8. Russian. (Мазуров В.И., Столов C.B., Зарайский М.И. Иммунологические механизмы в патогенезе коронарного атеросклероза. Терапевтический архив 2005; 77 (9): 24-8.</mixed-citation><mixed-citation xml:lang="en">Mazurov VI, Stolov CB, Zarajskij MI. The immunological mechanisms in the pathogenesis of coronary atherosclerosis Terapevticheskij arhiv. 2005; 77 (9): 24-8. Russian. (Мазуров В.И., Столов C.B., Зарайский М.И. Иммунологические механизмы в патогенезе коронарного атеросклероза. Терапевтический архив 2005; 77 (9): 24-8.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Firestein G, Panayiand G, Wollheim F. Rheumatoid arthritis. Oxford: Oxford University Press, 2006: 173-92.</mixed-citation><mixed-citation xml:lang="en">Firestein G, Panayiand G, Wollheim F. Rheumatoid arthritis. Oxford: Oxford University Press, 2006: 173-92.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690-7.</mixed-citation><mixed-citation xml:lang="en">Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690-7.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">López-Mejías R, García-Bermúdez M, González-Juanatey C, et al. NFKB-1 -94 ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2012; 224: 426-9.</mixed-citation><mixed-citation xml:lang="en">López-Mejías R, García-Bermúdez M, González-Juanatey C, et al. NFKB-1 -94 ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2012; 224: 426-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J. Rheumatol 2005; 32: 435-42.</mixed-citation><mixed-citation xml:lang="en">Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J. Rheumatol 2005; 32: 435-42.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">González-Gay MA, González-Juanatey C. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Annals of the Rheumatic Diseases 2014; 73 (7): 1281-3.</mixed-citation><mixed-citation xml:lang="en">González-Gay MA, González-Juanatey C. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Annals of the Rheumatic Diseases 2014; 73 (7): 1281-3.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">González-Gay MA, González-Juanatey C, Martin J. High –grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J. Rheumatol 2005; 32: 1219-23.</mixed-citation><mixed-citation xml:lang="en">González-Gay MA, González-Juanatey C, Martin J. High –grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J. Rheumatol 2005; 32: 1219-23.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">González-Gay MA, González-Juanatey C, Lopez-Diaz MJ, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125-32.</mixed-citation><mixed-citation xml:lang="en">González-Gay MA, González-Juanatey C, Lopez-Diaz MJ, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125-32.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Naumov AV. The efficacy and safety of diacerein in the therapy of chronic pain in osteoarthritis in patients with cardiovascular comorbidity in contraindications to NsAIDs. Poliklinika 2015; 4: 1-6. Russian (Наумов А.В. Эффективность и безопасность диацереина в терапии хронической боли при остеоартрите у пациентов с сердечно-сосудистой коморбидностью и противопоказаниями к НПВП. Поликлиника 2015; 4: 1-6.)</mixed-citation><mixed-citation xml:lang="en">Naumov AV. The efficacy and safety of diacerein in the therapy of chronic pain in osteoarthritis in patients with cardiovascular comorbidity in contraindications to NsAIDs. Poliklinika 2015; 4: 1-6. Russian (Наумов А.В. Эффективность и безопасность диацереина в терапии хронической боли при остеоартрите у пациентов с сердечно-сосудистой коморбидностью и противопоказаниями к НПВП. Поликлиника 2015; 4: 1-6.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nasonov EL, Mazurov VI, Karateev DE, et al. Project: recommendations on treatment of rheumatoid arthritis developed by all - Russian public organization «Association of rheumatologists of Russia»-2014 (part 1). Nauchno-prakticheskaja revmatologija 2015; 5s (53): 1-17. In Russian (Насонов Е.Л., Мазуров В.И., Каратеев Д.Е., и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» -2014 (часть 1). Научно-практическая ревматология 2015;5 s (53): 1-17).</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Mazurov VI, Karateev DE, et al. Project: recommendations on treatment of rheumatoid arthritis developed by all - Russian public organization «Association of rheumatologists of Russia»-2014 (part 1). Nauchno-prakticheskaja revmatologija 2015; 5s (53): 1-17. In Russian (Насонов Е.Л., Мазуров В.И., Каратеев Д.Е., и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» -2014 (часть 1). Научно-практическая ревматология 2015;5 s (53): 1-17).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Arnett FC, Edworthy SM, Bloch DA, et al. American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988; 31: 315-24.</mixed-citation><mixed-citation xml:lang="en">Arnett FC, Edworthy SM, Bloch DA, et al. American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988; 31: 315-24.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League against Rheumatism collaborative initiative 2010; 69: 1580-8.</mixed-citation><mixed-citation xml:lang="en">Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League against Rheumatism collaborative initiative 2010; 69: 1580-8.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Национальный стандарт Российской Федерации «Лаборатории медицинские. Частные требования к качеству и компетентности» (http://docs.cntd.ru/document/gost-r-iso-15189-2009, дата обращения 7.12.2015).</mixed-citation><mixed-citation xml:lang="en">Национальный стандарт Российской Федерации «Лаборатории медицинские. Частные требования к качеству и компетентности» (http://docs.cntd.ru/document/gost-r-iso-15189-2009, дата обращения 7.12.2015).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Roubille C, Richer V, Starnino T et al. The effects of TNF inhibitors, methotrexate, NSAIDs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases 2014; 73 (2): 126.</mixed-citation><mixed-citation xml:lang="en">Roubille C, Richer V, Starnino T et al. The effects of TNF inhibitors, methotrexate, NSAIDs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases 2014; 73 (2): 126.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
